Non-Alcoholic Steatohepatitis (NASH) Market To Reach USD 13.38 Billion By 2026 | Reports And Data
27 févr. 2019 08h33 HE
|
Reports And Data
Increasing prevalence of obesity coupled with rising adoption of sedentary lifestyle is the major factor influencing market growth. Market Size – USD 0.41 billion in 2018, Market Growth - CAGR of...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease as well as 2 Additional Lead Targets
14 janv. 2019 07h00 HE
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital
03 janv. 2019 11h10 HE
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease
01 nov. 2018 07h00 HE
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
06 sept. 2018 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the...
Non-alcoholic Steatohepatitis Biomarkers Market to reach a valuation of US$1.7 bn by 2024, Says TMR
31 juil. 2018 09h49 HE
|
Transparency Market Research
Albany, NY, July 31, 2018 (GLOBE NEWSWIRE) -- According to the market research study by Transparency Market Research, in 2016, the global market for NASH biomarkers was worth US$201.2 mn and is...
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
13 juin 2018 07h30 HE
|
Metacrine
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine Completes $65 Million Series C Financing
06 juin 2018 07h30 HE
|
Metacrine
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
31 mai 2018 16h05 HE
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
31 mai 2018 07h30 HE
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...